In our study, there were 34 patients with tumors and 85 patients diagnosed with abnormal tumor markers [including Alpha fetoprotein (AFP), CA125, CA242, CA72-4, CA50, CA19-9, carcinoembryonic antigen (CEA), Prostate specific antigen (t-PSA), Cytokeratin-19-fragment (CYFYA21-1), neuron specific enolase (NSE), Squamous cell carcinoma antigen (SCC), pro-gastrin-releasing peptide (ProGRP)]. This evidence concerns the gene GRP and neoplasm.